This is a multicenter, randomized, double-blind, placebo-controlled clinical trial (SLEDAIS) involving 1,040 patients with acute ischemic stroke (AIS) who require inter-hospital transfer for potential endovascular therapy. The study aims to evaluate the efficacy and safety of sublingual Edaravone Dexborneol tablets administered in the ultra-early stage (within 6 hours of symptom onset) during the critical inter-hospital transfer window.
Patients will be randomly assigned in a 1:1 ratio to receive either sublingual Edaravone Dexborneol (a loading dose of 4 tablets initially, followed by 1 tablet twice daily for 13 days) or a matching placebo. The primary efficacy endpoint is the functional outcome assessed by the modified Rankin Scale (mRS) score at 90 days. The primary safety endpoint is the mortality rate at 90 days. This study seeks to provide high-quality evidence for neuroprotection during the transfer period, potentially improving functional recovery for stroke patients.
Aged 18 to 80 years (inclusive).
Time from last known normal to arrival at the first hospital is within 6 hours.
Clinical and imaging diagnosis of acute ischemic stroke, with a Los Angeles Motor Scale (LAMS) score ≥ 4, or occlusion of the internal carotid artery, M1/M2 segment of the middle cerebral artery, V4 segment of the vertebral artery, or basilar artery confirmed by CTA/MRA at the first or target hospital.
ASPECTS score ≥ 6 on non-contrast head CT at the first hospital.
Allergy to contrast agents, nickel, titanium, or their alloys.
Known allergy to dexborneol, edaravone, or excipients.
Pre-stroke modified Rankin Scale (mRS) score ≥ 2.
Patients receiving intravenous thrombolysis alone.
Parallel
Edaravone dexborneol sublingual tablet
DrugEdaravone Dexborneol is a novel neuroprotective agent combining edaravone (a free radical scavenger) and dexborneol (an anti-inflammatory component) in a 5:1 ratio. In this study, participants in the experimental group will receive a loading dose of 4 sublingual tablets (each containing edaravone 30mg + dexborneol 6mg, total: edaravone 120mg + dexborneol 24mg) within 10 minutes after randomization during inter-hospital transfer. From day 2 to day 14, participants will receive 1 tablet twice daily. The sublingual formulation dissolves within 5 minutes, allowing rapid absorption through the sublingual venous plexus and bypassing hepatic first-pass effect. This high initial loading dose aims to rapidly establish therapeutic concentrations before endovascular therapy to provide neuroprotection during the critical transfer window.
Placebo
DrugMatching placebo sublingual tablets identical in appearance, smell, and packaging to the active drug. Participants will receive a loading dose of 4 placebo tablets (each containing 60μg dexborneol, a trace amount solely for maintaining blinding with no expected therapeutic effect) within 10 minutes after randomization. From day 2 to day 14, participants will receive 1 placebo tablet twice daily. The placebo is designed to be indistinguishable from Edaravone Dexborneol tablets to maintain the double-blind design.
Modified Rankin Scale (mRS) Score at 90 Days
Functional outcome assessed by the modified Rankin Scale (mRS) at 90 days post-randomization. The mRS is an ordinal scale ranging from 0 (no symptoms) to 6 (death), used to evaluate the degree of disability or dependence in daily activities.
Mortality Rate at 90 Days
All-cause mortality rate within 90 days post-randomization.
Infarct Volume at 36 Hours
Infarct volume (ml) measured by non-contrast CT or MRI-DWI at 36 hours post-procedure.
NIHSS Score at Discharge
National Institutes of Health Stroke Scale (NIHSS) score assessed at 5-7 days or at hospital discharge, whichever comes first.
Proportion of Patients With mRS 0-1 at 90 Days
Percentage of patients achieving excellent functional outcome (mRS score 0-1, indicating no symptoms or symptoms but no disability) at 90 days.
Proportion of Patients With mRS 0-2 at 90 Days
Percentage of patients achieving functional independence (mRS score 0-2, indicating no to mild disability but able to care for self) at 90 days.
Click on the lead sponsor to view all of their trials.
Xinqiao Hospital of Chongqing
Lead sponsor
Simcere Pharmaceutical Group Co., LTD
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
